Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
A 2026 biopharmaceutical review in a journal I do not trust said there is no identified high-affinity receptor, no validated molecular target, and a wide disconnect between the tidy preclinical effects and any coherent pharmacology
Another large-scale review of over 228,000 patient records found that GLP-1 medications like semaglutide were associated with a 22% lower rate of alcohol-related hospital visits
In one trial, tirzepatide was shown to cause weight loss of up to 22% in people with a BMI of 30 or higher and at least one associated health problem
Key Takeaways The use of GLP-1 diabetes and weight-loss medications is soaring among teens and young adults Prescription rates rose nearly 7-fold between 2020 and 2023 Researchers believe more caution may be needed, since there's still little data on the drugs' effects in this younger age group WEDNESDAY, May 22, 2024 (HealthDay News) -- The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report finds
